Guidepoint Qsight’s data captured a surge in spending on non-surgical medical aesthetics treatments in March and April 2021.
Neurotoxins, dermal fillers, and non-surgical skin tightening reached unprecedented levels in March 2021 with a continued strong growth trend into April, according to Qsight’s aesthetics point-of-sale data.
- Younger patients are contributing more to the 2021 aesthetic sales spike than patients over 60. In March and April 2021, spending by patients less than 40 years of age increased by +84.2% over the same months in 2019.
- Conversely, sales by patients over 60 years of age decreased slightly (-1.2%).
- A little more than half of aesthetics sales come from patients between 41-60 (51.4% in 2021)
- Younger patients (under the age of 40) contributed the most to the 2021 sales spike, growing their share of aesthetics sales by +8.6%, which could signal a longer-term trend of patients getting aesthetics procedures at younger ages.
Based on commentary from our proprietary panel of medical aesthetics practitioners, the strong demand in aesthetics procedures may be attributable to stimulus checks, an increase in disposable income, high demand going into post-COVID summer, or a mixture of all the above.
The question remains if this is a passing “perfect storm” or if this surge represents a bellwether for the multibillion-dollar industry for a new era of higher spending on medical aesthetics treatments in the U.S. by a younger demographic.
For more information about this analysis, and the trends we are seeing by practice type, treatment categories, gender, etc., contact us here.
Post created by: Travis Deseran, Director of Quantitative Research, Guidepoint Qsight and Shimul Sheth, Senior Quantitative Analyst, Guidepoint Qsigh